区块链技术:药品供应链管理的一个潜在工具
Wasim Akram1, Ramakant Joshi1, Tanweer Haider1
1Amity Institute of Pharmacy, Amity University, Madhya Pradesh, Gwalior, India.
Research in social & administrative pharmacy : RSAP
|February 29, 2024
概括
区块链技术通过提供透明,安全和不可变的系统来加强药品供应链管理,从原材料跟踪药物到患者. 这有助于提高监督和产品质量.
科学领域:
- 药品供应链管理的管理
- 区块链技术应用的应用
- 供应链可追溯性 供应链可追溯性
背景情况:
- 制药供应链涉及多个利益相关者,需要有效的可追溯系统.
- 数字化跟踪和追踪流程可以改善监管监督和产品质量.
- 区块链为制药供应链数据提供了一个分布式,不变和透明的平台.
研究的目的:
- 审查区块链技术在制药供应链管理中的意义和必要性.
主要方法:
- 从2017年1月到2023年9月进行了全面的文献审查.
- 审查的重点是区块链技术及其在供应链中的应用.
- 区块链被定义为记录交易的按时间顺序排序,加密安全的点对点网络.
主要成果:
- 区块链提供端到端的可见性和管理整个供应链的单一系统.
- 优势包括增强的安全性,可追溯性和允许各方之间改善的沟通.
- 区块链系统可以有效地跟踪,追踪和召回制药产品.
结论:
- 基于区块链的制药供应链管理跟踪从供应商到消费者之间的药物交易.
- 区块链通过透明度和不变性来增强供应链的安全性,完整性,数据来源和功能.
更多相关视频
相关概念视频
Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
Drug Control Governance: Regulatory Bodies and Their Impact
158
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
158
Drug Administration and Therapy Phases: Overview
462
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
462
Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
171
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
171


